Detail akcie QuidelOrtho Rg online

Business Summary: QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
Financial Summary: BRIEF: For the six months ended 29 June 2025, Quidelortho Corp revenues decreased 3% to $1.31B. Net loss decreased 86% to $268.1M. Revenues reflect North America segment decrease of 8% to $717.4M. Lower net loss reflects Goodwill impairment charge decrease from $1.74B (expense) to $0K, Asset impairment charge decrease from $56.9M (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$27.70 to -$3.96.